npj Vaccines (Nov 2024)

Neutralization of SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 by human and murine sera

  • Kun Xu,
  • Yaling An,
  • Xueyuan Liu,
  • Haitang Xie,
  • Dedong Li,
  • Ting Yang,
  • Minrun Duan,
  • Yuanzhuo Wang,
  • Xin Zhao,
  • Lianpai Dai,
  • George F. Gao

DOI
https://doi.org/10.1038/s41541-024-01016-6
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 6

Abstract

Read online

Abstract We report SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 neutralizing antibody titers. They displayed increased immune evasion compared to JN.1, especially KP.1 and KP.3, for participants who experienced BF.7/BA.5.2 breakthrough infection or received bivalent (delta/BA.5) vaccine boosting. Second XBB sub-variants breakthrough infection enhanced the neutralization responses. HK.3-JN.1 RBD-heterodimer induced balanced and potent neutralizing responses against recently-circulating SARS-CoV-2 sub-variants in mice, supporting to replace the COVID-19 antigen containing JN.1 or its sub-variants.